A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Jancik, Sylwia ^a   Drabek, Jiri ^a   Berkovcova, Jitka ^a   Xu, Yong Zhong ^b   Stankova, Marcela ^a,c   Klein, Jiri ^a   Kolek, Vitezslav ^a   Skarda, Josef ^a   Tichy, Tomas ^a   Grygarkova, Ivona ^a   Radzioch, Danuta ^b   Hajduch, Marian ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b MCGILL UNIVERSITY   (Canada)

^c Institute of Biotechnology   (Czech Republic)

Author keywords

Genotyping; KRAS Kiras2 kristen rat sarcoma viral oncogene homolog; NSCLC Non small cell lung cancer; SNP single nucleotide polymorphism

Indexed keywords

GENOMIC DNA; K RAS PROTEIN;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIRECT SEQUENCING; DNA EXTRACTION; GENE MUTATION; GENETIC PROCEDURES; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; K RAS STRIPASSAY; LUNG NON SMALL CELL CANCER; MEDICAL FEE; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; THERASCREEN DXS; WORKING TIME;

CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DNA, NEOPLASM; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84866483171     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-79     Document Type: Article

References (40)

1. Clinical relevance of KRAS in human cancers. Jancik S, Drabek J, Radzioch D, Hajduch M, J Biomed Biotechnol 2010 2010 150960. 1-13, Epub 2010 Jun 7
2. Lung cancer after treatment for breast cancer. Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N, Lancet Oncol 2010 11 1184 1192 10.1016/S1470-2045(10)70056-5 20541465
3. Second cancers after breast cancer treatment. Matesich SM, Shapiro CL, Semin Oncol 2003 30 740 748 10.1053/j.seminoncol.2003.08.022 14663775 (Pubitemid 38010128)
4. AKT signaling in physiology and disease. Vasudevan KM, Garraway LA, Curr Top Microbiol Immunol 2010 347 105 133 10.1007/82-2010-66 20549472
5. Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Hann CL, Brahmer JR, Curr Treat Options Oncol 2007 8 28 37 10.1007/s11864-007-0024-2 17634830
6. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Lievre A, Bachet JB, Boige V, Cayre A, Le CD, Buc E, et al. J Clin Oncol 2008 26 374 379 10.1200/JCO.2007.12. 5906 18202412 (Pubitemid 351171687)
7. KRAS testing and its importance in colorectal cancer. Patil DT, Fraser CR, Plesec TP, Curr Oncol Rep 2010 12 160 167 10.1007/s11912-010-0099-y 20425075
8. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. J Clin Oncol 2009 27 2091 2096 10.1200/JCO.2009.21.9170 19188670
9. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, et al. Cancer Chemother Pharmacol 2012 69 5 1289 1299 10.1007/s00280-012- 1829-7 22302407
10. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, et al. Eur Respir J 2012 40 1 177 184 Epub 2012 Jan 20 10.1183/09031936.00097311 22267755
11. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. Virchows Arch 2008 453 417 431 10.1007/s00428-008-0665-y 18802721
12. Pettersson E, Lundeberg J, Ahmadian A, Generations of sequencing technologies. Genomics 2009 93 105 111
13. KRAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in KRAS. Wojcik P, Kulig J, Okon K, Zazula M, Mozdzioch I, Niepsuj A, et al. Pol J Pathol 2008 59 93 96 18669174 (Pubitemid 352029608)
14. New comprehensive denaturing-gradient-gel-electrophoresis assay for KRAS mutation detection applied to paraffin-embedded tumours. Hayes VM, Westra JL, Verlind E, Bleeker W, Plukker JT, Hofstra RMW, et al. Genes Chromosomes Cancer 2000 29 309 314 10.1002/1098-2264(2000)9999:9999<::AID-GCC1037>3.0.CO;2-F 11066074
15. Alternative dideoxy sequencing of double-stranded DNA by cyclic reactions using Taq polymerase. Lee JS, DNA Cell Biol 1991 10 67 73 10.1089/dna.1991.10. 67 1671332
16. Long-read pyrosequencing using pure 2'-deoxyadenosine-5'-O'-(1- thiotriphosphate) Sp-isomer. Gharizadeh B, Nordstrom T, Ahmadian A, Ronaghi M, Nyren P, Anal Biochem 2002 301 82 90 10.1006/abio.2001.5494 11811970 (Pubitemid 34113681)
17. A sequencing method based on real-time pyrophosphate. Ronaghi M, Uhlen M, Nyren P, Science 1998 281 363 365 9705713 (Pubitemid 28340773)
18. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M, et al. J Mol Diagn 2010 12 292 299 10.2353/jmoldx.2010.090139 20203003
19. High-resolution genotyping by amplicon melting analysis using LCGreen. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ, Clin Chem 2003 49 853 860 10.1373/49.6.853 12765979 (Pubitemid 36623462)
20. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, et al. J Mol Diagn 2009 11 543 552 10.2353/jmoldx.2009. 090057 19815694
21. Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. Gao J, Li YY, Sun PN, Shen L, World Journal of Gastroenterology 2010 16 4858 4864 10.3748/wjg.v16.i38.4858 20939116
22. Laser capture microdissection in the tissue biorepository. Liu A, J Biomol Tech 2010 21 120 125 20808641
23. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, et al. Mod Pathol 2009 22 1023 1031 10.1038/modpathol.2009.59 19430420
24. Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Beau-Faller M, Legrain M, Voegeli AC, Guerin E, Lavaux T, Ruppert AM, et al. Br J Cancer 2009 100 985 992 10.1038/sj.bjc.6604925 19293811
25. Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. Pennycuick A, Simpson T, Crawley D, Lal R, Santis G, Cane P, et al. International Journal of Clinical Practice 2012 66 748 752 10.1111/j.1742-1241. 2012.02961.x 22805266
26. Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Pinto P, Rocha P, Veiga I, Guedes J, Pinheiro M, Peixoto A, et al. Cancer Genetics 2011 204 439 446 10.1016/j.cancergen.2011.07.003 21962894
27. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. J Mol Diagn 2010 12 425 432 10.2353/jmoldx.2010.090188 20431034
28. Sensitive Sequencing method for KRAS mutation detection by pyrosequencing. Ogino S, Kawasaki T, Brahmandam M, Yan LY, Cantor M, Namgyal C, et al. J Mol Diagn 2005 7 413 421 10.1016/S1525-1578(10)60571-5 16049314 (Pubitemid 41149657)
29. A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results. Chen G, Olson MT, O'Neill A, Norris A, Beierl K, Harada S, et al. J Mol Diagn 2012 14 149 159 10.1016/j.jmoldx.2011.12.001 22316529
30. Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Shen S, Qin D, Diagn Pathol 2012 7 56 10.1186/1746-1596-7-56 22640803
31. Detection of Somatic Mutations by High-Resolution DNA Melting (HRM) Analysis in Multiple Cancers. Gonzalez-Bosquet J, Calcei J, Wei JS, Garcia-Closas M, Sherman ME, Hewitt S, et al. PLoS ONE 2011 6 1 14522 10.1371/journal.pone.0014522 21264207
32. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase. Do HD, Dobrovic A, Oncotarget 2012 3 546 558 22643842
33. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, et al. J Mol Diagn 2010 12 35 42 10.2353/jmoldx.2010.090079 20007841
34. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. Borras E, Jurado I, Hernan I, Gamundi MJ, Dias M, Marti I, et al. BMC Cancer 2011 11 406 10.1186/1471-2407-11-406 21943394
35. High-resolution melting analysis (HRMA): more than just sequence variant screening. Vossen RH, Aten E, Roos A, Den Dunnen JT, Hum Mutat 2009 30 860 866 10.1002/humu.21019 19418555
36. SNP genotyping by unlabeled probe melting analysis. Erali M, Palais R, Wittwer C, Methods Mol Biol 2008 429 199 206 10.1007/978-1-60327-040-3-14 18695968
37. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, et al. J Mol Diagn 2012 14 247 255 10.1016/j.jmoldx.2012.01.011 22425762
38. TVBaFrost 1: Uniting local Frozen Tumour Banks into a European Network: an overview. Riegman P, Dinjens W, Oomen M, Spatz A, Ratcliffe C, Knoxc K, et al. Eur J Cancer 2006 42 2678 2683 10.1016/j.ejca.2006.04.031 17027254 (Pubitemid 44739988)
39. Using Whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage Non-small cell lung cancer (NSCLC). Lim EH, Zhang SL, Li XL, Yap WS, Howe TC, Tan BP, et al. J Thorac Oncol 2009 4 12 21 10.1097/JTO.0b013e3181913e28 19096301
40. Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. van Eijk R, van Puijenbroek M, Chhatta AR, Gupta N, Vossen RH, Lips EH, et al. J Mol Diagn 2010 12 27 34 10.2353/jmoldx.2010.090028 19959798